* Loss/shr $0.30 vs yr-ago loss/shr $0.25
* Records non-cash charge of $2.5 mln
* Shares down 4 pct after market
Aug 12 (Reuters) - Oncothyreon Inc posted a wider second-quarter net loss due to a non-cash charge and lower revenue resulting from the transfer of manufacturing activities for Stimuvax cancer vaccine to Merck KGaA in Dec 2008.
The transfer resulted in a decrease in both contract manufacturing and licensing revenue from collaborative agreements, the company said in a statement.
Total revenue fell to $31,000, from $1.2 million in the year-ago period.
For the quarter ended June 30, the company posted a net loss of $6.3 million, or 30 cents a share, compared with a net loss of $4.9 million, or 25 cents a share, a year ago.
Oncothyreon recorded a non-cash charge of $2.5 million in the quarter for the change in the fair value of warrants related to its securities offering in May, the company said in a statement.
Shares of the company were down 4 percent at $5.70 in after market trade. They closed at $5.94 Wednesday on Nasdaq.
For the alerts, please double-click
(Reporting by Shailesh Kuber in Bangalore; Editing by Anil D'Silva) Keywords: ONCOTHYREON/ (shailesh.kuber@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: shailesh.kuber.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Records non-cash charge of $2.5 mln
* Shares down 4 pct after market
Aug 12 (Reuters) - Oncothyreon Inc posted a wider second-quarter net loss due to a non-cash charge and lower revenue resulting from the transfer of manufacturing activities for Stimuvax cancer vaccine to Merck KGaA in Dec 2008.
The transfer resulted in a decrease in both contract manufacturing and licensing revenue from collaborative agreements, the company said in a statement.
Total revenue fell to $31,000, from $1.2 million in the year-ago period.
For the quarter ended June 30, the company posted a net loss of $6.3 million, or 30 cents a share, compared with a net loss of $4.9 million, or 25 cents a share, a year ago.
Oncothyreon recorded a non-cash charge of $2.5 million in the quarter for the change in the fair value of warrants related to its securities offering in May, the company said in a statement.
Shares of the company were down 4 percent at $5.70 in after market trade. They closed at $5.94 Wednesday on Nasdaq.
For the alerts, please double-click
(Reporting by Shailesh Kuber in Bangalore; Editing by Anil D'Silva) Keywords: ONCOTHYREON/ (shailesh.kuber@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: shailesh.kuber.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.